RosettaCommons/UTexasAptamer huggingface dataset:
Aptamer: Apt70
Target: Interleukin 2 receptor alpha (IL2Rα CD25)
Type of nucleic acid: ssDNA
Sequence: 5′GCTGTGTGACTCCTGCAAGCGGGAAGAGGGCAGGGGTGGGAGGGTAACGCGGAAAGGGCAAGCAGCTGTATCTTGTCTCC3'
Sequence length: 80
GC content: 0.6125
Affinity: Kd: 138.6 nM
Pool type: 5′-GCTGTGTGACTCCTGCAA-N43-GCAGCTGTATCTTGTCTCC-3′
Pool random region: 43
Binding buffer/conditions: 50 mM K2HPO4 pH 7.5, 150 mM NaCl, 0.05% Tween-20, BSA 1 μg/ml, 0.1 mg/ml yeast tRNA
Buffer type: PBS/phosphate buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " High levels of CD25, as part of the IL-2 receptor, are expressed on the surface of the activated T lymphocytes and regulatory T cells, indicating that the soluble CD25 (sCD25) could be a clinically valuable tool for treating several diseases. In the current study, generation of an ssDNA aptamer (Apt51) against CD25 is reported. Apt51 bound to CD25 with high affinity (Kd=13.4nM) and specificity. Apt51 showed good affinity and selectivity for the recognition of CD25 on the cell surface. Importantly, the study showed that Apt51 interfered with the binding of CD25 to its ligand (IL 2) and consequently decreased the IL-2-induced Akt activation."
Reference (2017, Int Immunopharmacol ): Shahdordizadeh, M., Taghdisi, S. M., Sankian, M., Ramezani, M., & Abnous, K. (2017). Design, isolation and evaluation of the binding efficiency of a DNA aptamer against interleukin 2 receptor alpha, in vitro. International immunopharmacology, 53, 96–104. https://doi.org/10.1016/j.intimp.2017.10.011
Aptamer: MF11
Target: Chemokine CCL17
Type of nucleic acid: ssRNA
Sequence: 5'AAUAGAGUCGUCGCGGGUUGGCUCGUAGAUCGGGCCGGUACAGACGACUCGCUGAGGAUCCGAGA3'
Sequence length: 65
GC content: 0.6
Affinity: Not reported
Pool type: 5′-GGGGGAATTCTAATACGACTCACTATA-N40-CAGACGACTCGCTGAGGATCCGAGA-3′
Pool random region: 40
Binding buffer/conditions: PBS [pH 7.4], 1 mM MgCl2, 1 mM CaCl2
Divalent salt: MgCl/CaCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " The chemokine CCL17, mainly produced by dendritic cells (DCs) in the immune system, is involved in the pathogenesis of various inflammatory diseases. We report the identification of two novel RNA aptamers, which were validated in vitro and in vivo for their capability to neutralize CCL17. Potentially, CCL17-specific aptamers may be used therapeutically in humans to treat or prevent allergic and inflammatory diseases."
Reference (2017, Mol Ther ): Fülle, L., Steiner, N., Funke, M., Gondorf, F., Pfeiffer, F., Siegl, J., Opitz, F. V., Haßel, S. K., Erazo, A. B., Schanz, O., Stunden, H. J., Blank, M., Gröber, C., Händler, K., Beyer, M., Weighardt, H., Latz, E., Schultze, J. L., Mayer, G., & Förster, I. (2018). RNA Aptamers Recognizing Murine CCL17 Inhibit T Cell Chemotaxis and Reduce Contact Hypersensitivity In Vivo. Molecular therapy : the journal of the American Society of Gene Therapy, 26(1), 95–104. https://doi.org/10.1016/j.ymthe.2017.10.005
Aptamer: MF35
Target: Chemokine CCL17
Type of nucleic acid: ssRNA
Sequence: 5'GAGCAGCAUUUGUGGUUUCCCGAUCGCUUCCCCUAAACAGCAGACGACUCGCUGAGGAUCCGAGA3'
Sequence length: 65
GC content: 0.5538461538461539
Affinity: Not reported
Pool type: 5′-GGGGGAATTCTAATACGACTCACTATA-N40-CAGACGACTCGCTGAGGATCCGAGA-3′
Pool random region: 40
Binding buffer/conditions: PBS [pH 7.4], 1 mM MgCl2, 1 mM CaCl2
Divalent salt: MgCl/CaCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Therapeutic: " The chemokine CCL17, mainly produced by dendritic cells (DCs) in the immune system, is involved in the pathogenesis of various inflammatory diseases. We report the identification of two novel RNA aptamers, which were validated in vitro and in vivo for their capability to neutralize CCL17. Potentially, CCL17-specific aptamers may be used therapeutically in humans to treat or prevent allergic and inflammatory diseases."
Reference (2017, Mol Ther ): Fülle, L., Steiner, N., Funke, M., Gondorf, F., Pfeiffer, F., Siegl, J., Opitz, F. V., Haßel, S. K., Erazo, A. B., Schanz, O., Stunden, H. J., Blank, M., Gröber, C., Händler, K., Beyer, M., Weighardt, H., Latz, E., Schultze, J. L., Mayer, G., & Förster, I. (2018). RNA Aptamers Recognizing Murine CCL17 Inhibit T Cell Chemotaxis and Reduce Contact Hypersensitivity In Vivo. Molecular therapy : the journal of the American Society of Gene Therapy, 26(1), 95–104. https://doi.org/10.1016/j.ymthe.2017.10.005
Aptamer: MF11.46
Target: Chemokine CCL17
Type of nucleic acid: ssRNA
Sequence: 5'GGGUCGUCGCGGGUUGGCUCGUAGAUCGGGCCGGUACAGACGACCCAGACGACUCGCUGAGGAUCCGAGA3'
Sequence length: 70
GC content: 0.6571428571428571
Affinity: Kd: 0.9 ± 0.1 nM
Pool type: 5′-GGGGGAATTCTAATACGACTCACTATA-N40-CAGACGACTCGCTGAGGATCCGAGA-3′
Pool random region: 40
Binding buffer/conditions: PBS [pH 7.4], 1 mM MgCl2, 1 mM CaCl2
Divalent salt: MgCl/CaCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Truncated version of mf11 aptamer
Application as quoted in the referenced paper: Therapeutic: " The chemokine CCL17, mainly produced by dendritic cells (DCs) in the immune system, is involved in the pathogenesis of various inflammatory diseases. We report the identification of two novel RNA aptamers, which were validated in vitro and in vivo for their capability to neutralize CCL17. Potentially, CCL17-specific aptamers may be used therapeutically in humans to treat or prevent allergic and inflammatory diseases."
Reference (2017, Mol Ther ): Fülle, L., Steiner, N., Funke, M., Gondorf, F., Pfeiffer, F., Siegl, J., Opitz, F. V., Haßel, S. K., Erazo, A. B., Schanz, O., Stunden, H. J., Blank, M., Gröber, C., Händler, K., Beyer, M., Weighardt, H., Latz, E., Schultze, J. L., Mayer, G., & Förster, I. (2018). RNA Aptamers Recognizing Murine CCL17 Inhibit T Cell Chemotaxis and Reduce Contact Hypersensitivity In Vivo. Molecular therapy : the journal of the American Society of Gene Therapy, 26(1), 95–104. https://doi.org/10.1016/j.ymthe.2017.10.005
Aptamer: MF35.47
Target: Chemokine CCL17
Type of nucleic acid: ssRNA
Sequence: 5'GAGCAGCAUUUGUGGUUUCCCGAUCGCUUCCC3'
Sequence length: 32
GC content: 0.5625
Affinity: Kd: 7.5 ± 1.5 nM
Pool type: 5′-GGGGGAATTCTAATACGACTCACTATA-N40-CAGACGACTCGCTGAGGATCCGAGA-3′
Pool random region: 40
Binding buffer/conditions: PBS [pH 7.4], 1 mM MgCl2, 1 mM CaCl2
Divalent salt: MgCl/CaCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Truncated version of mf35 aptamer
Application as quoted in the referenced paper: Therapeutic: " The chemokine CCL17, mainly produced by dendritic cells (DCs) in the immune system, is involved in the pathogenesis of various inflammatory diseases. We report the identification of two novel RNA aptamers, which were validated in vitro and in vivo for their capability to neutralize CCL17. Potentially, CCL17-specific aptamers may be used therapeutically in humans to treat or prevent allergic and inflammatory diseases."
Reference (2017, Mol Ther ): Fülle, L., Steiner, N., Funke, M., Gondorf, F., Pfeiffer, F., Siegl, J., Opitz, F. V., Haßel, S. K., Erazo, A. B., Schanz, O., Stunden, H. J., Blank, M., Gröber, C., Händler, K., Beyer, M., Weighardt, H., Latz, E., Schultze, J. L., Mayer, G., & Förster, I. (2018). RNA Aptamers Recognizing Murine CCL17 Inhibit T Cell Chemotaxis and Reduce Contact Hypersensitivity In Vivo. Molecular therapy : the journal of the American Society of Gene Therapy, 26(1), 95–104. https://doi.org/10.1016/j.ymthe.2017.10.005
Aptamer: Aptamer-20
Target: Insulin like growth factor II receptor (IGFIIR), Homo sapien
Type of nucleic acid: ssDNA
Sequence: 5'AGAGTGCTGTTACTATCGGGGCGCGTAGATGACGAGCAGTCCTAACATCGTTTAGGACAACTGAACAAGGTGGTAT3'
Sequence length: 76
GC content: 0.4868421052631579
Affinity: Kd: 35.5 nM
Pool type: 5'-AGAGTGCTGTTACTATCG-N40-AACTGAACAAGGTGGTAT-3'
Pool random region: 40
Binding buffer/conditions: PBS containing 0.05% Tween 20 and 20 mM Tris, 500 mM imidazole pH 7.5
Buffer type: PBS/phosphate buffers
pH: 7.5
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic: " Insulin like growth factor II receptor (IGFIIR) is a transmembrane protein overexpressed in activated hepatic stellate cells (HSCs), which are the major target for the treatment of liver fibrosis. In this study, we aim to discover an IGFIIR-specific aptamer that can be potentially used as a targeting ligand for the treatment and diagnosis of liver fibrosis. These data suggest that aptamer-20 is a high-affinity ligand for antifibrotic and diagnostic agents for liver fibrosis."
Reference (2017, Theranostics ): Chen, Z., Liu, H., Jain, A., Zhang, L., Liu, C., & Cheng, K. (2017). Discovery of Aptamer Ligands for Hepatic Stellate Cells Using SELEX. Theranostics, 7(12), 2982–2995. https://doi.org/10.7150/thno.19374
Aptamer: ML12
Target: Lethal factor (LF): one of three toxins produced by Bacillus anthracis (B. anthracis)
Type of nucleic acid: ssDNA
Sequence: 5′GCGCGGATCCCGCGCCGAGGGAGACGCGAACCTTCTCGCCTTGGGCGCGCGAAGCTTGCG3′
Sequence length: 60
GC content: 0.7333333333333333
Affinity: Kd: 11.0 ± 2.7 nM via gel shift assay & 530 ± 11 nM via nonlinear fitting of the saturation binding curve from ELISA. IC50: 15 ± 1.5 μM
Pool type: 5′-GCGCGGATCCCGCGC-N30-CGCGCGAAGCTTGCG-3′
Pool random region: 30
Binding buffer/conditions: 30 mM Tris-HCl at pH 8.4, 3.0 mM KCl, 600 mM NaCl, and 0.6 mM MgCl2
Divalent salt: MgCl
Buffer type: Tris Buffers
pH: 8.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Detection and Therapeutic: " Anthrax is caused by Bacillus anthracis, a bacterium that is able to secrete the toxins protective antigen, edema factor and lethal factor. Due to the high level of secretion from the bacteria and its severe virulence, lethal factor (LF) has been sought as a biomarker for detecting bacterial infection and as an effective target to neutralize toxicity. In this study, we found three aptamers, and binding affinity was determined by fluorescently labeled aptamers. This aptamer provides a potential clue for not only development of a sensitive diagnostic device of B. anthracis infection but also the design of novel inhibitors of LF."
Reference (2018, Arch Biochem Biophys ): Lahousse, M., Park, H. C., Lee, S. C., Ha, N. R., Jung, I. P., Schlesinger, S. R., Shackelford, K., Yoon, M. Y., & Kim, S. K. (2018). Inhibition of anthrax lethal factor by ssDNA aptamers. Archives of biochemistry and biophysics, 646, 16–23. https://doi.org/10.1016/j.abb.2018.03.028
Aptamer: OD64
Target: Odontogenic ameloblast-associated protein (ODAM), Human
Type of nucleic acid: ssDNA
Sequence: 5'CCATTCGTACGCAACAGGGATGCATCGACTGTAAACACGTGGATGGCTCTGAATGC3'
Sequence length: 56
GC content: 0.5178571428571429
Affinity: Kd: 47.71 nM
Pool type: 5'CCATTCGTACGCAACAGG-N20-GTGGATGGCTCTGAATGC3'
Pool random region: 20
Binding buffer/conditions: 10 mM PBS
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Biosensor and Diagnostic: " This research aims to develop biosensors which could diagnose periodontal diseases in early phases and predict the illness stage of patients, in order to give them adequate treatment timely. Human odontogenic ameloblast-associated protein (ODAM) is considered to be a potential biomarker for periodontal diseases. This research shows the potential for implementation of a cognate pair of aptamers on point-of-care biosensors which enables simple, rapid, and non-invasive saliva-based diagnosis of periodontal-related diseases that can overcome current diagnostic methods and improve health care system."
Reference (2018, Biosens Bioelectron ): Lee, B. H., Kim, S. H., Ko, Y., Park, J. C., Ji, S., & Gu, M. B. (2019). The sensitive detection of ODAM by using sandwich-type biosensors with a cognate pair of aptamers for the early diagnosis of periodontal disease. Biosensors & bioelectronics, 126, 122–128. https://doi.org/10.1016/j.bios.2018.10.040
Aptamer: OD35
Target: Odontogenic ameloblast-associated protein (ODAM), Human
Type of nucleic acid: ssDNA
Sequence: 5'CCATTCGTACGCAACAGGCGACCTAAACAACGCATCAGGTGGATGGCTCTGAATGC3'
Sequence length: 56
GC content: 0.5357142857142857
Affinity: Kd: 51.36 nM
Pool type: 5'CCATTCGTACGCAACAGG-N20-GTGGATGGCTCTGAATGC3'
Pool random region: 20
Binding buffer/conditions: 10 mM PBS
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Biosensor and Diagnostic: " This research aims to develop biosensors which could diagnose periodontal diseases in early phases and predict the illness stage of patients, in order to give them adequate treatment timely. Human odontogenic ameloblast-associated protein (ODAM) is considered to be a potential biomarker for periodontal diseases. This research shows the potential for implementation of a cognate pair of aptamers on point-of-care biosensors which enables simple, rapid, and non-invasive saliva-based diagnosis of periodontal-related diseases that can overcome current diagnostic methods and improve health care system."
Reference (2018, Biosens Bioelectron ): Lee, B. H., Kim, S. H., Ko, Y., Park, J. C., Ji, S., & Gu, M. B. (2019). The sensitive detection of ODAM by using sandwich-type biosensors with a cognate pair of aptamers for the early diagnosis of periodontal disease. Biosensors & bioelectronics, 126, 122–128. https://doi.org/10.1016/j.bios.2018.10.040
Aptamer: sk1
Target: Breast cancer cell line SK-BR-3, Human
Type of nucleic acid: ssDNA
Sequence: 5'AGCAGAGTTCACGACCCGATAAGGGGAAAACACATTTCGGATCTCCGTTGTCGCCCTGATACCGAGTTACATACCAATCGTCGCAG3'
Sequence length: 86
GC content: 0.5116279069767442
Affinity: Kd:1.64 ± 0.52 nM
Pool type: 5′-AGCAGAGTTCACGACCCGATAAG-N40-GAGTTACATACCAATCGTCGCAG-3′
Pool random region: 40
Binding buffer/conditions: Phosphate-buffered saline (PBS, pH 7.4), 4.5 g/L glucose, 5 mM MgCl2, 0.1 mg/mL yeast tRNA, and 1 mg/mL bovine serum albumin
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " Molecular subtyping of breast cancer is of considerable interest owing to its potential for personalized therapy and prognosis. The aim of the present study is to develop a cell-specific single-stranded DNA (ssDNA) aptamer-based fluorescence probe for molecular subtyping of breast cancer. The results suggest that the aptamer-based probe is a powerful tool for fast and highly sensitive subtyping of breast cancer both in vitro and in vivo and is also very promising for the identification, diagnosis, and targeted therapy of breast cancer molecular subtypes."
Reference (2018, Theranostics ): Liu, M., Wang, Z., Tan, T., Chen, Z., Mou, X., Yu, X., Deng, Y., Lu, G., & He, N. (2018). An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer. Theranostics, 8(20), 5772–5783. https://doi-org.ezproxy.lib.utexas.edu/10.7150/thno.28949
Aptamer: sk2
Target: Breast cancer cell line SK-BR-4, Human
Type of nucleic acid: ssDNA
Sequence: 5'AGCAGAGTTCACGACCCGATAAGGGCGATGCCGATCCCTGTGGCCGTAGGGACAGTCCCGCTAGAGTTACATACCAATCGTCGCAG3'
Sequence length: 86
GC content: 0.5813953488372093
Affinity: Kd: 1.69 ± 0.38 nM
Pool type: 5′-AGCAGAGTTCACGACCCGATAAG-N40-GAGTTACATACCAATCGTCGCAG-3′
Pool random region: 40
Binding buffer/conditions: Phosphate-buffered saline (PBS, pH 7.4), 4.5 g/L glucose, 5 mM MgCl2, 0.1 mg/mL yeast tRNA, and 1 mg/mL bovine serum albumin
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " Molecular subtyping of breast cancer is of considerable interest owing to its potential for personalized therapy and prognosis. The aim of the present study is to develop a cell-specific single-stranded DNA (ssDNA) aptamer-based fluorescence probe for molecular subtyping of breast cancer. The results suggest that the aptamer-based probe is a powerful tool for fast and highly sensitive subtyping of breast cancer both in vitro and in vivo and is also very promising for the identification, diagnosis, and targeted therapy of breast cancer molecular subtypes."
Reference (2018, Theranostics ): Liu, M., Wang, Z., Tan, T., Chen, Z., Mou, X., Yu, X., Deng, Y., Lu, G., & He, N. (2018). An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer. Theranostics, 8(20), 5772–5783. https://doi-org.ezproxy.lib.utexas.edu/10.7150/thno.28949
Aptamer: sk3
Target: Breast cancer cell line SK-BR-5, Human
Type of nucleic acid: ssDNA
Sequence: 5'AGCAGAGTTCACGACCCGATAAGGGGAAAACACATTTCGGATCTCCGTTGTCGCCCTGGTACCGAGTTACATACCAATCGTCGCAG3'
Sequence length: 86
GC content: 0.5232558139534884
Affinity: Kd: 3.92 ± 1.22 nM
Pool type: 5′-AGCAGAGTTCACGACCCGATAAG-N40-GAGTTACATACCAATCGTCGCAG-3′
Pool random region: 40
Binding buffer/conditions: Phosphate-buffered saline (PBS, pH 7.4), 4.5 g/L glucose, 5 mM MgCl2, 0.1 mg/mL yeast tRNA, and 1 mg/mL bovine serum albumin
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " Molecular subtyping of breast cancer is of considerable interest owing to its potential for personalized therapy and prognosis. The aim of the present study is to develop a cell-specific single-stranded DNA (ssDNA) aptamer-based fluorescence probe for molecular subtyping of breast cancer. The results suggest that the aptamer-based probe is a powerful tool for fast and highly sensitive subtyping of breast cancer both in vitro and in vivo and is also very promising for the identification, diagnosis, and targeted therapy of breast cancer molecular subtypes."
Reference (2018, Theranostics ): Liu, M., Wang, Z., Tan, T., Chen, Z., Mou, X., Yu, X., Deng, Y., Lu, G., & He, N. (2018). An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer. Theranostics, 8(20), 5772–5783. https://doi-org.ezproxy.lib.utexas.edu/10.7150/thno.28949
Aptamer: sk4
Target: Breast cancer cell line SK-BR-6, Human
Type of nucleic acid: ssDNA
Sequence: 5'AGCAGAGTTCACGACCCGATAAGGGGAAAATACATTTCGGATCTCCGTTGTCGCCCTGATACCGAGTTACATACCAATCGTCGCAG3'
Sequence length: 86
GC content: 0.5
Affinity: Kd: 2.01± 0.58 nM
Pool type: 5′-AGCAGAGTTCACGACCCGATAAG-N40-GAGTTACATACCAATCGTCGCAG-3′
Pool random region: 40
Binding buffer/conditions: Phosphate-buffered saline (PBS, pH 7.4), 4.5 g/L glucose, 5 mM MgCl2, 0.1 mg/mL yeast tRNA, and 1 mg/mL bovine serum albumin
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " Molecular subtyping of breast cancer is of considerable interest owing to its potential for personalized therapy and prognosis. The aim of the present study is to develop a cell-specific single-stranded DNA (ssDNA) aptamer-based fluorescence probe for molecular subtyping of breast cancer. The results suggest that the aptamer-based probe is a powerful tool for fast and highly sensitive subtyping of breast cancer both in vitro and in vivo and is also very promising for the identification, diagnosis, and targeted therapy of breast cancer molecular subtypes."
Reference (2018, Theranostics ): Liu, M., Wang, Z., Tan, T., Chen, Z., Mou, X., Yu, X., Deng, Y., Lu, G., & He, N. (2018). An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer. Theranostics, 8(20), 5772–5783. https://doi-org.ezproxy.lib.utexas.edu/10.7150/thno.28949
Aptamer: sk5
Target: Breast cancer cell line SK-BR-7, Human
Type of nucleic acid: ssDNA
Sequence: 5'AGCAGAGTTCACGACCCGATAAGGGGAAAATACATTTCGGATCTCCGTTGTCGCCCTGGTACCGAGTTACATACCAATCGTCGCAG3'
Sequence length: 86
GC content: 0.5116279069767442
Affinity: Kd: 3.47 ± 0.90 nM
Pool type: 5′-AGCAGAGTTCACGACCCGATAAG-N40-GAGTTACATACCAATCGTCGCAG-3′
Pool random region: 40
Binding buffer/conditions: Phosphate-buffered saline (PBS, pH 7.4), 4.5 g/L glucose, 5 mM MgCl2, 0.1 mg/mL yeast tRNA, and 1 mg/mL bovine serum albumin
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " Molecular subtyping of breast cancer is of considerable interest owing to its potential for personalized therapy and prognosis. The aim of the present study is to develop a cell-specific single-stranded DNA (ssDNA) aptamer-based fluorescence probe for molecular subtyping of breast cancer. The results suggest that the aptamer-based probe is a powerful tool for fast and highly sensitive subtyping of breast cancer both in vitro and in vivo and is also very promising for the identification, diagnosis, and targeted therapy of breast cancer molecular subtypes."
Reference (2018, Theranostics ): Liu, M., Wang, Z., Tan, T., Chen, Z., Mou, X., Yu, X., Deng, Y., Lu, G., & He, N. (2018). An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer. Theranostics, 8(20), 5772–5783. https://doi-org.ezproxy.lib.utexas.edu/10.7150/thno.28949
Aptamer: sk6
Target: Breast cancer cell line SK-BR-8, Human
Type of nucleic acid: ssDNA
Sequence: 5'AGCAGAGTTCACGACCCGATAAGGGCGATGCCGATCCCTGTGGCCGTAGGGGCAGTCCCGCTAGAGTTACATACCAATCGTCGCAG3'
Sequence length: 86
GC content: 0.5930232558139535
Affinity: Kd: 0.61 ± 0.14 nM
Pool type: 5′-AGCAGAGTTCACGACCCGATAAG-N40-GAGTTACATACCAATCGTCGCAG-3′
Pool random region: 40
Binding buffer/conditions: Phosphate-buffered saline (PBS, pH 7.4), 4.5 g/L glucose, 5 mM MgCl2, 0.1 mg/mL yeast tRNA, and 1 mg/mL bovine serum albumin
Divalent salt: MgCl
Buffer type: PBS/phosphate buffers
pH: 7.4
Molecular weight of target: Not reported
Post-SELEX modifications: Not applicable
Application as quoted in the referenced paper: Diagnostic and Therapeutic: " Molecular subtyping of breast cancer is of considerable interest owing to its potential for personalized therapy and prognosis. The aim of the present study is to develop a cell-specific single-stranded DNA (ssDNA) aptamer-based fluorescence probe for molecular subtyping of breast cancer. The results suggest that the aptamer-based probe is a powerful tool for fast and highly sensitive subtyping of breast cancer both in vitro and in vivo and is also very promising for the identification, diagnosis, and targeted therapy of breast cancer molecular subtypes."
Reference (2018, Theranostics ): Liu, M., Wang, Z., Tan, T., Chen, Z., Mou, X., Yu, X., Deng, Y., Lu, G., & He, N. (2018). An Aptamer-Based Probe for Molecular Subtyping of Breast Cancer. Theranostics, 8(20), 5772–5783. https://doi-org.ezproxy.lib.utexas.edu/10.7150/thno.28949